Literature DB >> 9141633

Heregulin degradation in the absence of rapid receptor-mediated internalization.

J Baulida1, G Carpenter.   

Abstract

Heregulin receptors are unable to mediate the rapid internalization of bound ligand as demonstrated in cells transfected with chimeric or wild-type ErbB-2, -3, or -4 receptors (Baulida et al., 1996, J. Biol. Chem. 271, 5251-5257; Pinkas-Kramanski et al., 1996, EMBO J. 15, 2452-2467). This observation is now extended to include mammary carcinoma cell lines (SK-BR-3 and MDA-543) which express endogenous ErbB-2 and ErbB-3 receptors. Also, the fate of receptor-bound heregulin is examined. While receptor-bound heregulin is not rapidly internalized, the ligand is subject to a slow process of inactivation and degradation, which requires heregulin incubation at 37 degrees C with cells that express heregulin receptors. The degradation of heregulin is blocked to a significant extent by chloroquine, an inhibitor of endosome fusion with lysosomes, indicating that heregulin is slowly internalized and degraded. However, this process is not sufficiently rapid to produce ligand-dependent down-regulation of heregulin receptors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9141633     DOI: 10.1006/excr.1997.3515

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  16 in total

1.  Selective targeting and inducible destruction of human cancer cells by retroviruses with envelope proteins bearing short peptide ligands.

Authors:  Timothy J Gollan; Michael R Green
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Association with membrane protrusions makes ErbB2 an internalization-resistant receptor.

Authors:  Anette M Hommelgaard; Mads Lerdrup; Bo van Deurs
Journal:  Mol Biol Cell       Date:  2004-01-23       Impact factor: 4.138

3.  Activated ErbB3 Translocates to the Nucleus via Clathrin-independent Endocytosis, Which Is Associated with Proliferating Cells.

Authors:  Raymond Reif; Alshaimaa Adawy; Nachiket Vartak; Jutta Schröder; Georgia Günther; Ahmed Ghallab; Marcus Schmidt; Wiebke Schormann; Jan G Hengstler
Journal:  J Biol Chem       Date:  2015-12-30       Impact factor: 5.157

4.  Structural insights into the down-regulation of overexpressed p185(her2/neu) protein of transformed cells by the antibody chA21.

Authors:  Huihao Zhou; Zhao Zha; Yang Liu; Hongtao Zhang; Juanjuan Zhu; Siyi Hu; Guodong Shen; Liansheng Cheng; Liwen Niu; Mark I Greene; Maikun Teng; Jing Liu
Journal:  J Biol Chem       Date:  2011-06-16       Impact factor: 5.157

5.  Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1.

Authors:  Zhongwei Cao; Xiuli Wu; Lily Yen; Colleen Sweeney; Kermit L Carraway
Journal:  Mol Cell Biol       Date:  2007-01-08       Impact factor: 4.272

Review 6.  Cross-talk and modulation of signaling between somatostatin and growth factor receptors.

Authors:  Ujendra Kumar
Journal:  Endocrine       Date:  2011-08-26       Impact factor: 3.633

7.  Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological response.

Authors:  Harish Shankaran; H Steven Wiley; Haluk Resat
Journal:  Biophys J       Date:  2006-03-13       Impact factor: 4.033

Review 8.  Endocytosis and intracellular trafficking of ErbBs.

Authors:  Alexander Sorkin; Lai Kuan Goh
Journal:  Exp Cell Res       Date:  2008-08-28       Impact factor: 3.905

9.  Regulation of ErbB-4 endocytosis by neuregulin in GABAergic hippocampal interneurons.

Authors:  M Longart; M Chatani-Hinze; C M Gonzalez; D Vullhorst; A Buonanno
Journal:  Brain Res Bull       Date:  2007-03-19       Impact factor: 4.077

10.  HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.

Authors:  Bart E C G de Goeij; Matthias Peipp; Simone de Haij; Edward N van den Brink; Christian Kellner; Thilo Riedl; Rob de Jong; Tom Vink; Kristin Strumane; Wim K Bleeker; Paul W H I Parren
Journal:  MAbs       Date:  2014-01-03       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.